- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06373419
방광 종양의 일괄 절제술에서 TFL 대 MOSES 홀뮴 레이저
방광 종양 일괄 절제술에서 TFL(툴륨 섬유 레이저)과 MOSES 홀뮴 레이저 비교: 무작위 대조 임상 연구
The goal of this randomized clinical trial is to determine if there is difference in pathological and clinical outcomes between MOSES and TFL in the transurethral laser enucleation of bladder tumors.
The main question it aims to answer is:
Is there a difference in pathological and clinical outcomes between MOSES Holmium and Thulium Fiber Laser (TFL) in the transurethral laser enucleation of bladder tumors?
Participants will randomized to either TFL of MOSES arm for their bladder resection procedure.
연구 개요
상세 설명
An estimated 12,500 Canadians are diagnosed with bladder cancer each year. Diagnosis and treatment involve transurethral (through the urethra) resection of tumor or tissue called the TURBT procedure. This procedure yields excellent results and minimal morbidity and mortality but has a high recurrence rate, difficulties in the pathologic interpretation of the specimen (due to cautery effect), and procedure-related complications (excessive bleeding, bladder perforation, bowel injury, and inadvertent extensive injury to urethra) that may delay treatments such as chemotherapy which would further impact oncologic outcomes. With the advancement of technology, new methods of transurethral tumor removal have emerged, such as the use of laser energy. Using laser energy, the tumour is resected in one piece, whereas the TURBT approach requires breaking the tumor into pieces. This allows for better pathology analysis that can determine treatment pathways for the patient, as well as reduces the risk of complications. The standard lasers used have been the MOSES Holmium laser and the Thulium Fiber Laser (TFL).
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ontario
-
Thunder Bay, Ontario, 캐나다, P7B 6V4
- Thunder Bay Regional Health Sciences Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Over 18 years of age at the time of enrollment.
- Patients presented with visual criteria suggesting bladder tumor by outpatient cystoscopy will be legible for inclusion.
Exclusion Criteria:
- Tumors deemed not eligible for laser resection as determined by the Urologist e.g. obvious muscle-invasive or metastatic at presentation
- Synchronous either urethral tumors or upper urinary tract tumor
- History of Carcinoma in situ
- Contracted bladder
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Thulium Fibre Laser
Participants randomized to this arm will undergo bladder resection using the TFL laser |
Participant undergoing bladder tumour resection that has been randomized to this arm. |
|
활성 비교기: MOSES Holmonium
Participants randomized to this arm will undergo bladder resection using the MOSES holmium laser. |
Participant undergoing bladder tumour resection that has been randomized to this arm. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Presence of muscularis propria
기간: 1 day post-procesure
|
Presence of muscularis propria (bladder muscle cells) in the pathology sample of the bladder tumour |
1 day post-procesure
|
|
Incidence of inconclusive pathology
기간: 1 day post-procedure
|
Incidence of inconclusive pathology due to specimen artifact |
1 day post-procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Tumor-free rate (TFR)
기간: 6 to 12 weeks post-procedure
|
As per the follow-up cystoscopy, TFR is defined as the absence of any residual tumor detectable by cystoscopy. |
6 to 12 weeks post-procedure
|
|
Total operative time
기간: Intraoperative
|
In minutes measured from anesthesia induction until placement of the urethral catheter |
Intraoperative
|
|
Total procedural time
기간: Intraoperative
|
In minutes, measured from the time the cystoscope sheath is inserted into the participant to the time the cystoscope has been removed |
Intraoperative
|
|
Number of recurrences
기간: 12 weeks post-procedure
|
Defined as any tumor detection by follow-up cystoscopy after the initial resection |
12 weeks post-procedure
|
|
Total blood loss
기간: 6 hours post-procedure
|
Defined as a drop in hemoglobin level from pre-op |
6 hours post-procedure
|
|
Rate of complications
기간: 4 weeks post-procedure
|
Percentage of participants with post-operative complications |
4 weeks post-procedure
|
|
Number of inconclusive pathology
기간: 1 day post-procedure
|
Number of inconclusive pathology due to thermal effect artifact. |
1 day post-procedure
|
|
Lasing time
기간: Intraoperative
|
In minutes, defined as the time the laser was in use, not including pedal pauses |
Intraoperative
|
|
Total energy used
기간: Intraoperative
|
Measured in kilojoules |
Intraoperative
|
|
Frequency and severity of peri-operative complications
기간: Intraoperative
|
Reported according to Clavien-Dindo |
Intraoperative
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ahmed Z Ahmed, Thunder Bay Regional Health Sciences Centre
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RP-1007
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .